Company profile
Celldex Therapeutics, Inc.
NASDAQ: CLDX · Healthcare · Biotechnology
#825 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
58CFH 46DQ 85GM 26SS 87
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ operating margin, net margin
Methodology →Revenue TTM
$820.0k
Rev growth YoY (TTM)
-89.2%
Net income (FY)
-$258.8M
Employees
198
as of 2026-08-08
Market cap
$2.8B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.5M$1.5M2025
Net income-$258.8M-$258.8M2025
Operating income-$287.4M-$287.4M2025
Total assets$583.0M$583.0M2025
Liabilities$55.8M$55.8M2025
Equity$527.2M$527.2M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Grant94%
Service6%
By geography
Not disclosed.
The read
What is Celldex Therapeutics, Inc.’s revenue?
Celldex Therapeutics, Inc. booked $1.5M in FY2025 revenue, contracting 78% year over year — slower than 87% of Healthcare companies we track, at a -16748.0% net margin.
Peers · Healthcare
Cannabis Global Inc.——BG Medicine, Inc.——Acura Pharmaceuticals, Inc.——Orthometrix, Inc.——Molecule Holdings Inc.——New Leaf Ventures Inc——Key facts
CEOAnthony S. Marucci
SectorHealthcare
IndustryBiotechnology
HeadquartersHampton, NJ
ExchangeNASDAQ: CLDX
Employees198
IPO date1986-05-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.